In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program
Novartis is still in the race to win the world’s first approval for a pioneering CAR-T treatment.
The pharma giant $NVS pulled back the veil …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
